专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明专利

AU780535B2 Compositions for stimulating cytokine secretion and inducing an immune response 未知
公开(公告)号：AU780535B2
公开(公告)日：2005-03-24
申请号：AU6813900
申请日：2000-08-28
申请人： INEX PHARMACEUTICALS CORP
发明人： SEMPLE SEAN C , HARASYM TROY O , KLIMUK SANDRA K , KOJIC LJILJIANA D , BRAMSON JONATHAN L , MUI BARBARA , HOPE MICHAEL J
IPC分类号： A61K9/00 , A61K9/127 , A61K31/711 , A61K38/00 , A61K39/39 , A61K47/48 , A61P37/02 , A61P37/04 , A61P43/00
摘要： Lipid-nucleic acid particles can provide therapeutic benefits, even when the nucleic acid is not complementary to coding sequences in target cells. It has been found that lipid-nucleic acid particles, including those containing non-sequence specific oligodeoxynucleotides, can be used to stimulate cytokine secretion, thus enhancing the overall immune response of a treated mammal. Further, immune response to specific target antigens can be induced by administration of an antigenic molecule in association with lipid particles containing non-sequence specific oligodeoxynucleotides. The nucleic acid which is included in the lipid-nucleic acid particle can be a phosphodiester (i.e., an oligodeoxynucleotide consisting of nucleotide residues joined by phosphodiester linkages) or a modified nucleic acid which includes phosphorothioate or other modified linkages, and may suitably be one which is non-complementary to the human genome, such that it acts to provide immunostimulation in a manner which is independent of conventional base-pairing interactions between the nucleic acid and nucleic acids of the treated mammal. In particular, the nucleic acid may suitably contain an immune-stimulating motif such as a CpG motif, or an immune stimulating palindromic sequence. The cationic lipid included in the nucleic acid particles may be suitably selected from among DODAP, DODMA, DMDMA, DOTAP, DC-Chol, DDAB, DODAC, DMRIE, DOSPA and DOGS. In addition, the lipid particle may suitably contain a modified aggregation-limiting lipid such as a PEG-lipid, a PAO-lipid or a ganglioside.

12. 发明专利

HU0202327A2 COMPOSITIONS FOR STIMULATING CYTOKINE SECRETION AND INDUCING AN IMMUNE RESPONSE 未知
公开(公告)号：HU0202327A2
公开(公告)日：2002-10-28
申请号：HU0202327
申请日：2000-08-28
申请人： INEX PHARMACEUTICALS CORP
发明人： BRAMSON JONATHAN L , HARASYM TROY O , HOPE MICHAEL J , KLIMUK SANDRA K , KOJIC LJILJIANA D , MUI BARBARA , SEMPLE SEAN C
IPC分类号： A61K9/00 , A61K9/127 , A61K31/711 , A61K38/00 , A61K39/39 , A61K47/48 , A61P37/02 , A61P37/04 , A61P43/00
摘要： Lipid-nucleic acid particles can provide therapeutic benefits, even when the nucleic acid is not complementary to coding sequences in target cells. It has been found that lipid-nucleic acid particles, including those containing non-sequence specific oligodeoxynucleotides, can be used to stimulate cytokine secretion, thus enhancing the overall immune response of a treated mammal. Further, immune response to specific target antigens can be induced by administration of an antigenic molecule in association with lipid particles containing non-sequence specific oligodeoxynucleotides. The nucleic acid which is included in the lipid-nucleic acid particle can be a phosphodiester (i.e., an oligodeoxynucleotide consisting of nucleotide residues joined by phosphodiester linkages) or a modified nucleic acid which includes phosphorothioate or other modified linkages, and may suitably be one which is non-complementary to the human genome, such that it acts to provide immunostimulation in a manner which is independent of conventional base-pairing interactions between the nucleic acid and nucleic acids of the treated mammal. In particular, the nucleic acid may suitably contain an immune-stimulating motif such as a CpG motif, or an immune stimulating palindromic sequence. The cationic lipid included in the nucleic acid particles may be suitably selected from among DODAP, DODMA, DMDMA, DOTAP, DC-Chol, DDAB, DODAC, DMRIE, DOSPA and DOGS. In addition, the lipid particle may suitably contain a modified aggregation-limiting lipid such as a PEG-lipid, a PAO-lipid or a ganglioside.

13. 发明专利

AT219660T 未知
公开(公告)号：AT219660T
公开(公告)日：2002-07-15
申请号：AT95932591
申请日：1995-09-29
申请人： INEX PHARMACEUTICALS CORP
发明人： ANSELL STEVEN MICHIAL , MUI BARBARA , HOPE MICHAEL
IPC分类号： A61K9/127 , A61K48/00 , C12N15/87 , C12N15/88
摘要： The present invention provides compositions and methods which are useful for the introduction of polyanionic materials into cells. The compositions are mixtures of cationic compounds and neutral lipids which are typically formulated as liposomes. The cationic compounds are quaternary ammonium compounds wherein the nitrogen has two attached long chain alkyl groups, at least one of which is unsaturated. The methods for transfecting cells involve (a) contacting the polyanionic materials with the compositions above to form a polyanionic material-liposome complex, and (b) contacting the complex with the cells to be transfected.

14. 发明专利

CA2382611A1 COMPOSITIONS FOR STIMULATING CYTOKINE SECRETION AND INDUCINGAN IMMUNE RESPONSE 未知
公开(公告)号：CA2382611A1
公开(公告)日：2001-03-08
申请号：CA2382611
申请日：2000-08-28
申请人： INEX PHARMACEUTICALS CORP
发明人： HOPE MICHAEL J , KOJIC LJILJIANA D , BRAMSON JONATHAN L , MUI BARBARA , SEMPLE SEAN C , KLIMUK SANDRA K , HARASYM TROY O
IPC分类号： A61K9/00 , A61K9/127 , A61K31/711 , A61K38/00 , A61K39/39 , A61K47/48 , A61P37/02 , A61P37/04 , A61P43/00 , A61P35/00 , A61K31/7088
摘要： Lipid-nucleic acid particles can provide therapeutic benefits, even when the nucleic acid is not complementary to coding sequences in target cells. It ha s been found that lipid-nucleic acid particles, including those containing non - sequence specific oligodeoxynucleotides, can be used to stimulate cytokine secretion, thus enhancing the overall immune response of a treated mammal. Further, immune response to specific target antigens can be induced by administration of an antigenic molecule in association with lipid particles containing non-sequence specific oligodeoxynucleotides. The nucleic acid whi ch is included in the lipid-nucleic acid particle can be a phosphodiester (i.e. , an oligodeoxynucleotide consisting of nucleotide residues joined by phosphodiester linkages) or a modified nucleic acid which includes phosphorothioate or other modified linkages, and may suitably be one which i s non-complementary to the human genome, such that it acts to provide immunostimulation in a manner which is independent of conventional base- pairing interactions between the nucleic acid and nucleic acids of the treat ed mammal. In particular, the nucleic acid may suitably contain an immune- stimulating motif such as a CpG motif, or an immune stimulating palindromic sequence. The cationic lipid included in thenucleic acid particles may be suitably selected from among DODAP, DODMA, DMDMA, DOTAP, DC-Chol, DDAB, DODA C, DMRIE, DOSPA and DOGS. In addition, the lipid particle may suitably contain a modified aggregation-limiting lipid such as a PEG-lipid, a PAO-lipid or a ganglioside.

15. 发明专利

DE60036950D1 未知
公开(公告)号：DE60036950D1
公开(公告)日：2007-12-13
申请号：DE60036950
申请日：2000-08-28
申请人： INEX PHARMACEUTICALS CORP
发明人： SEMPLE SEAN C , HARASYM TROY O , KLIMUK SANDRA K , KOJIC LJILJIANA D , BRAMSON JONATHAN L , MUI BARBARA , HOPE MICHAEL J
IPC分类号： A61K39/39 , A61K9/00 , A61K9/127 , A61K31/7088 , A61K31/711 , A61K35/00 , A61K38/00 , A61K47/48 , A61P37/02 , A61P37/04 , A61P43/00
摘要： Lipid-nucleic acid particles can provide therapeutic benefits, even when the nucleic acid is not complementary to coding sequences in target cells. It has been found that lipid-nucleic acid particles, including those containing non-sequence specific oligodeoxynucleotides, can be used to stimulate cytokine secretion, thus enhancing the overall immune response of a treated mammal. Further, immune response to specific target antigens can be induced by administration of an antigenic molecule in association with lipid particles containing non-sequence specific oligodeoxynucleotides. The nucleic acid which is included in the lipid-nucleic acid particle can be a phosphodiester (i.e., an oligodeoxynucleotide consisting of nucleotide residues joined by phosphodiester linkages) or a modified nucleic acid which includes phosphorothioate or other modified linkages, and may suitably be one which is non-complementary to the human genome, such that it acts to provide immunostimulation in a manner which is independent of conventional base-pairing interactions between the nucleic acid and nucleic acids of the treated mammal. In particular, the nucleic acid may suitably contain an immune-stimulating motif such as a CpG motif, or an immune stimulating palindromic sequence. The cationic lipid included in the nucleic acid particles may be suitably selected from among DODAP, DODMA, DMDMA, DOTAP, DC-Chol, DDAB, DODAC, DMRIE, DOSPA and DOGS. In addition, the lipid particle may suitably contain a modified aggregation-limiting lipid such as a PEG-lipid, a PAO-lipid or a ganglioside.

16. 发明专利

DE69527206T2 未知
公开(公告)号：DE69527206T2
公开(公告)日：2003-02-27
申请号：DE69527206
申请日：1995-09-29
申请人： INEX PHARMACEUTICALS CORP
发明人： ANSELL STEVEN MICHIAL , MUI BARBARA , HOPE MICHAEL
IPC分类号： A61K9/127 , A61K48/00 , C12N15/87 , C12N15/88
摘要： The present invention provides compositions and methods which are useful for the introduction of polyanionic materials into cells. The compositions are mixtures of cationic compounds and neutral lipids which are typically formulated as liposomes. The cationic compounds are quaternary ammonium compounds wherein the nitrogen has two attached long chain alkyl groups, at least one of which is unsaturated. The methods for transfecting cells involve (a) contacting the polyanionic materials with the compositions above to form a polyanionic material-liposome complex, and (b) contacting the complex with the cells to be transfected.

17. 发明专利

DE69527206D1 未知
公开(公告)号：DE69527206D1
公开(公告)日：2002-08-01
申请号：DE69527206
申请日：1995-09-29
申请人： INEX PHARMACEUTICALS CORP
发明人： ANSELL STEVEN MICHIAL , MUI BARBARA , HOPE MICHAEL
IPC分类号： A61K9/127 , A61K48/00 , C12N15/87 , C12N15/88
摘要： The present invention provides compositions and methods which are useful for the introduction of polyanionic materials into cells. The compositions are mixtures of cationic compounds and neutral lipids which are typically formulated as liposomes. The cationic compounds are quaternary ammonium compounds wherein the nitrogen has two attached long chain alkyl groups, at least one of which is unsaturated. The methods for transfecting cells involve (a) contacting the polyanionic materials with the compositions above to form a polyanionic material-liposome complex, and (b) contacting the complex with the cells to be transfected.

18. 发明专利

BR0013834A 未知
公开(公告)号：BR0013834A
公开(公告)日：2002-04-23
申请号：BR0013834
申请日：2000-08-28
申请人： INEX PHARMACEUTICALS CORP
发明人： SEMPLE SEAN C , HARASYM TROY O , KLIMUK SANDRA K , KOJIC LJILJIANA D , BRAMSON JONATHAN L , MUI BARBARA , HOPE MICHAEL J
IPC分类号： A61K9/00 , A61K9/127 , A61K31/711 , A61K38/00 , A61K39/39 , A61K47/48 , A61P37/02 , A61P37/04 , A61P43/00
摘要： Lipid-nucleic acid particles can provide therapeutic benefits, even when the nucleic acid is not complementary to coding sequences in target cells. It has been found that lipid-nucleic acid particles, including those containing non-sequence specific oligodeoxynucleotides, can be used to stimulate cytokine secretion, thus enhancing the overall immune response of a treated mammal. Further, immune response to specific target antigens can be induced by administration of an antigenic molecule in association with lipid particles containing non-sequence specific oligodeoxynucleotides. The nucleic acid which is included in the lipid-nucleic acid particle can be a phosphodiester (i.e., an oligodeoxynucleotide consisting of nucleotide residues joined by phosphodiester linkages) or a modified nucleic acid which includes phosphorothioate or other modified linkages, and may suitably be one which is non-complementary to the human genome, such that it acts to provide immunostimulation in a manner which is independent of conventional base-pairing interactions between the nucleic acid and nucleic acids of the treated mammal. In particular, the nucleic acid may suitably contain an immune-stimulating motif such as a CpG motif, or an immune stimulating palindromic sequence. The cationic lipid included in the nucleic acid particles may be suitably selected from among DODAP, DODMA, DMDMA, DOTAP, DC-Chol, DDAB, DODAC, DMRIE, DOSPA and DOGS. In addition, the lipid particle may suitably contain a modified aggregation-limiting lipid such as a PEG-lipid, a PAO-lipid or a ganglioside.

19. 发明专利

AU3559595A Novel compositions for the introduction of polyanionic materials into cells 未知
公开(公告)号：AU3559595A
公开(公告)日：1996-04-26
申请号：AU3559595
申请日：1995-09-29
申请人： INEX PHARMACEUTICALS CORP
发明人： ANSELL STEVEN MICHIAL , MUI BARBARA , HOPE MICHAEL
IPC分类号： A61K9/127 , A61K47/44 , A61K48/00 , C12N15/87 , C12N15/88
摘要： The present invention provides compositions and methods which are useful for the introduction of polyanionic materials into cells. The compositions are mixtures of cationic compounds and neutral lipids which are typically formulated as liposomes. The cationic compounds are quaternary ammonium compounds wherein the nitrogen has two attached long chain alkyl groups, at least one of which is unsaturated. The methods for transfecting cells involve (a) contacting the polyanionic materials with the compositions above to form a polyanionic material-liposome complex, and (b) contacting the complex with the cells to be transfected.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式